Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03379584 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03379584 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 14 participants.
The verdict
NCT03379584, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.
Interventions
- DRUG SGN-CD48A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2019-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03379584
The ClinicalTrials.gov registry entry for NCT03379584 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD48A is the first listed.
NCT03379584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03379584 about?
NCT03379584 is a clinical study titled "A Safety Study of SGN-CD48A in Patients With Multiple Myeloma". This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.
What is the current status of trial NCT03379584?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2018-02-20. Estimated completion is 2019-08-23.
What interventions are being tested in trial NCT03379584?
The interventions under investigation include: SGN-CD48A (DRUG).
Who is sponsoring clinical trial NCT03379584?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.